Will Sherwin-Williams' 'Paint Shield' reduce hospital infections?
The new b...
U.S.-based paint manufacturer Sherwin-Williams claims to have created a paint that will kill bacteria, and its main target will be hospitals.
The new brand called “Paint Shield” is believed to kill all bacteria that lands on it within about two hours. It has recently been certified by the U.S. Environmental Protection Agency for eliminating 99.9 percent of bacteria including Staph, E. coli and MRSA.
“This is one of the most significant technological breakthroughs in our nearly 150-year history of innovation,” said Sherwin-Williams CEO Chris Connor. “By killing infectious pathogens on painted surfaces, Paint Shield is a game-changing advancement in coatings technology.”
According to the U.S. Department of Health and Human Services — as well as the CDC — about one in 25 patients contract at least one healthcare-associated infection during their hospital stay. Not only are these infections a main cause of hospital fatalities, but are also very expensive.
Data from the CDC in 2009 revealed healthcare-associated infections cost U.S. hospitals between $28-45 billion per year in direct medical costs.
RELATED TOPIC: TOP 10: Best hospitals to work for in the Northeast USA
Paint Shield was developed at Sherwin-Williams’ Cleveland, Ohio, headquarters after consulting with infectious disease specialists. It will be available in 590 different colors in over 4,000 U.S. retail outlets in the first quarter of 2016, and is believed to be effective for up to four years.
Sherwin-Williams is the second-largest paint manufacturer in the U.S. with an 11.3 percent market share.
However, not everyone views this latest type of paint as a significant technological breakthrough. Doctor Emily Landon, the University of Chicago hospital epidemiologist, isn’t certain the product will have a major effect in medical centers.
Landon is currently the head of limiting the spread of infections at the hospital, and wants to see more research on the effectiveness of reducing infections before becoming an advocate of Paint Shield.
“Bacteria don’t jump off of walls, and the only way it can get from walls to patients in from contaminated health care provider hands,” said Landon. “In a daycare center or a pediatrician waiting room, where you’ve got kids running around with snotty noses all the time, it may be helpful to have fewer bacteria on the wall. But that really remains to be seen.”
Click here to read the latest edition of Healthcare Global magazine!
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.